The global anti-obesity drugs market is projected to grow from 19.6 billion dollars in 2025 to 104.9 billion dollars by 2035, driven by rising obesity rates and new drug innovations.

Roche announces positive Phase I trial results for CT-996, a new oral GLP-1 receptor agonist for type 2 diabetes and obesity. The study shows significant weight loss and good tolerability, paving the way for further development.